Noxilizer, Inc. Raises $30M for Sterilization Technology

Noxilizer, Inc., a provider of ultra-low temperature sterilization technology, has secured $30,000,000 in new investment capital from investors. This significant funding round will fuel the company's strategic growth and expansion initiatives. Noxilizer, Inc. specializes in nitrogen dioxide sterilization, which operates at ultra-low temperatures ranging from 10°C to 30°C. This technology offers distinct advantages over traditional sterilization methods, providing a gentler and more efficient solution for sensitive materials. The company serves the pharmaceutical, biotech, and medical device industries by both selling its advanced sterilization equipment and offering comprehensive contract sterilization services at its facilities in Baltimore, MD. Noxilizer's dedicated team of experts in microbiology and material compatibility collaborates with clients to address complex sterilization challenges throughout the entire process. This substantial capital infusion underscores investor confidence in Noxilizer's proprietary technology and its potential to meet evolving demands within critical healthcare sectors. The company plans to strategically deploy the funds to accelerate its growth initiatives, including expanding its operational capabilities, scaling manufacturing of its sterilization equipment, and enhancing its contract sterilization service offerings to broaden its market reach. The funding positions Noxilizer, Inc. for significant expansion and innovation. The company aims to further establish its ultra-low temperature nitrogen dioxide sterilization technology as a preferred solution, enabling it to solidify its leadership in advanced sterilization and continue its trajectory of growth within the pharmaceutical, biotech, and medical device markets.